Merck Presents New Cardio-Pulmonary Data at ACC.26
- Phase 3 CORALreef AddOn trial evaluates enlicitide decanoate, an oral PCSK9 inhibitor.
- Phase 2 CADENCE trial assesses WINREVAIR™ (sotatercept-csrk) for CpcPH-HFpEF.
- Data presented at ACC.26 in New Orleans from March 28-30.
- Merck's trials focus on hypercholesterolemia and pulmonary hypertension.
Phase 3 CORALreef AddOn Trial
The Phase 3 CORALreef AddOn trial evaluates the efficacy and safety of enlicitide decanoate, an investigational oral PCSK9 inhibitor. This trial compares enlicitide against ezetimibe, bempedoic acid, and a combination of ezetimibe and bempedoic acid in adults with hypercholesterolemia who are already on statin therapy.
Phase 2 CADENCE Trial
The Phase 2 CADENCE trial focuses on WINREVAIR™ (sotatercept-csrk) in patients with the syndrome of combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF). This trial aims to address the limited treatment options available for this distinct syndrome.
ACC.26 Presentation
Merck will present these findings at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) in New Orleans, Louisiana, from March 28-30. The presentations will highlight Merck's ongoing research efforts in addressing cardiovascular diseases and pulmonary hypertension.
Source: Merck